TMP-195

Research use only, not for human use.

A first-in-class, potent, selective class IIa HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) inhibtior with IC50 of 60, 59, 26, and 15 nM, respectively.

A first-in-class, potent, selective class IIa HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) inhibtior with IC50 of 60, 59, 26, and 15 nM, respectively; shows no significant inhibition for others HDACs; alters the tumour microenvironment and reduces tumour burden and pulmonary metastases by modulating macrophage phenotypes in mice; induces the recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumours.

——

——

TMP 195 | TMP195

Cell Cycle/DNA Damage

HDAC

HDAC4|HDAC5|HDAC7|HDAC9

Cancer

——

1314891-22-9

456.42

C23H19F3N4O3

>98% (HPLC)

DMSO: 82 mg/mL (179.7 mM) （ < 1 mg/ml refers to the product slightly soluble or insoluble )

O=C(NCC(C1=COC(C2=CC=CC=C2)=N1)(C)C)C3=CC=CC(C4=NOC(C(F)(F)F)=N4)=C3

N-(2-methyl-2-(2-phenyloxazol-4-yl)propyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide

(-20℃)

With Ice Pack

≥ 2 years